Primary Myelofibrosis

• 

  Subject Areas on Research

  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. 
  • ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. 
  • Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. 
  • Diagnosis and management of myeloproliferative disorders. 
  • Diffuse intraabdominal lymphoma complicating idiopathic myelofibrosis: CT demonstration. 
  • Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. 
  • Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. 
  • FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia. 
  • Focal intrahepatic extramedullary hematopoiesis mimicking neoplasm. 
  • Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. 
  • Hodgkin's disease presenting as myelofibrosis. 
  • Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. 
  • Massive eyelid thickening in pachydermoperiostosis with myelofibrosis. 
  • Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. 
  • Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. 
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. 
  • Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. 
  • Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation. 
  • Ruxolitinib: a new treatment for myelofibrosis. 
  • Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study. 
  • Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual. 
  • Survival following allogeneic transplant in patients with myelofibrosis. 
  • The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. 
  • The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. 
  • Xist RNA is a potent suppressor of hematologic cancer in mice. 
  • β-Arrestin2 mediates progression of murine primary myelofibrosis.